We recommend that Phase II trials of STING-targeted therapies prospectively stratify TNBC patients based on composite biomarkers, such as CIN scores and STING/ENPP1 protein expression assessed by standardized IHC. The gene discussed is STING1; the disease is cervical squamous intraepithelial neoplasia.